🟢 Ligand Pharmaceuticals is trading 4.8% up in pre-market as biotech ETF XBI gains 3.64%

Ligand Pharmaceuticals is trading at $320.99, up 4.76%, with the move appearing primarily sector-led.

• Biotech ETF XBI was up 3.64% pre-market amid broad healthcare rotation and positive industry news.
• No fresh company-specific announcement was found for October 21. Bank of America’s Buy rating and price-target increase to $406 from $388 were reported October 19; third-quarter results are scheduled for October 29.